BIIB Q1 2022 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q1 2022 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$2.5B-6.0% YoY

Gross Profit

$1.8B70.2% margin

Operating Income

$524M20.7% margin

Net Income

$304M12.0% margin

EPS (Diluted)

$2.06

QoQ Revenue Growth

-7.4%

Cash Flow

Operating Cash Flow

$162M

Free Cash Flow

$104M

Stock-Based Comp.

$68M

Balance Sheet

Total Assets

$23.6B

Total Liabilities

$12.4B

Stockholders' Equity

$11.2B

Cash & Equivalents

$1.7B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.5B	$2.7B	-6.0%
Gross Profit	$1.8B	$2.2B	-19.8%
Operating Income	$524M	$974M	-46.2%
Net Income	$304M	$410M	-25.9%

Revenue Segments

MS Product Revenues

$1.4B43%

Fumarate

$538M17%

TYSABRI product

$521M16%

SPINRAZA

$473M15%

Interferon

$310M10%

Geographic Segments

Non-US

$1.2B58%

UNITED STATES

$875M42%